GSK Boosts Stake In Theravance, An Apparent Nod To The Biotech's Respiratory Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline raises its stake in Relovair partner Theravance to 19% in a $129.4 million investment that extends the biopharma's cash runway.